Q32 Bio Inc. Common Stock
QTTBQ32 Bio Inc. is a biotechnology company focused on developing novel therapies for rare and underserved diseases. The company leverages its expertise in drug discovery and development to create innovative treatments aimed at improving patient outcomes.
Company News
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...
